Literature DB >> 25804933

Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial.

Meghan Karuturi1, Anas Younes2, Luis Fayad1, Larry Kwak1, Barbara Pro3, Jatin Shah1, Yasuhiro Oki1, Rinata Simien1, Mary Joy Liboon1, Toni Hutto1, Lei Feng4, Sandra Horowitz1, Yago Nieto5, Paolo Anderlini5, Amin Alousi5, Uday Popat5, L Jeffrey Medeiros6, Roberto Miranda6, Michelle Fanale1.   

Abstract

Entities:  

Year:  2015        PMID： 25804933      PMCID： PMC5215977          DOI： 10.3109/10428194.2015.1032966

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  9 in total

Review 1.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Authors:  B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

2.  Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.

Authors:  Norbert Schmitz; Beate Pfistner; Michael Sextro; Markus Sieber; Angelo M Carella; Matthias Haenel; Friederike Boissevain; Reinhart Zschaber; Peter Müller; Hartmut Kirchner; Andreas Lohri; Susanne Decker; Bettina Koch; Dirk Hasenclever; Anthony H Goldstone; Volker Diehl
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

3.  Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma.

Authors:  Anas Younes; Barbara Pro; Luis Fayad
Journal:  Blood       Date:  2006-02-15       Impact factor: 22.113

4.  Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma.

Authors:  Michelle Fanale; Luis Fayad; Barbara Pro; Felipe Samaniego; Mary Joy Liboon; Cesar Nunez; Sandra Horowitz; Paolo Anderlini; Uday Popat; Yuan Ji; Larry W Kwak; Anas Younes
Journal:  Br J Haematol       Date:  2011-04-26       Impact factor: 6.998

5.  A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.

Authors:  C H Moskowitz; S D Nimer; A D Zelenetz; T Trippett; E E Hedrick; D A Filippa; D Louie; M Gonzales; J Walits; N Coady-Lyons; J Qin; R Frank; J R Bertino; A Goy; A Noy; J P O'Brien; D Straus; C S Portlock; J Yahalom
Journal:  Blood       Date:  2001-02-01       Impact factor: 22.113

6.  Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.

Authors:  Craig H Moskowitz; Matt J Matasar; Andrew D Zelenetz; Stephen D Nimer; John Gerecitano; Paul Hamlin; Steven Horwitz; Alison J Moskowitz; Ariela Noy; Lia Palomba; Miguel-Angel Perales; Carol Portlock; David Straus; Jocelyn C Maragulia; Heiko Schoder; Joachim Yahalom
Journal:  Blood       Date:  2011-12-19       Impact factor: 22.113

7.  Adaptive assignment versus balanced randomization in clinical trials: a decision analysis.

Authors:  D A Berry; S G Eick
Journal:  Stat Med       Date:  1995-02-15       Impact factor: 2.373

8.  Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.

Authors:  D C Linch; D Winfield; A H Goldstone; D Moir; B Hancock; A McMillan; R Chopra; D Milligan; G V Hudson
Journal:  Lancet       Date:  1993-04-24       Impact factor: 79.321

9.  Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

Authors:  N L Bartlett; D Niedzwiecki; J L Johnson; J W Friedberg; K B Johnson; K van Besien; A D Zelenetz; B D Cheson; G P Canellos
Journal:  Ann Oncol       Date:  2007-04-10       Impact factor: 32.976
  9 in total
  3 in total

Review 1.  Pharmacotherapeutic Management of Pediatric Lymphoma.

Authors:  Christine Mauz-Körholz; Natascha Ströter; Julia Baumann; Ante Botzen; Katharina Körholz; Dieter Körholz
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022

2.  Reed-Sternberg cells in Hodgkin's lymphoma present features of cellular senescence.

Authors:  J Gopas; E Stern; U Zurgil; J Ozer; A Ben-Ari; G Shubinsky; A Braiman; R Sinay; J Ezratty; V Dronov; S Balachandran; D Benharroch; E Livneh
Journal:  Cell Death Dis       Date:  2016-11-10       Impact factor: 8.469

Review 3.  Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies.

Authors:  Theodoros P Vassilakopoulos; John V Asimakopoulos; Kostas Konstantopoulos; Maria K Angelopoulou
Journal:  Ther Adv Hematol       Date:  2020-02-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.